BioWorld MedTech

Jan. 11, 2016

Diabetic Foot Ulcer Market: Omnigraft approval seen as catalyst for Integra, DFU market

A new FDA approval is expected to be an important catalyst for Integra Lifesciences Corp. (Plainsboro, N.J.) and represents a step in the right direction for the broader diabetic foot ulcer (DFU) market. Read More

Inside the Beltway: Hatch, Wyden urge CMS to redo PAMA reporting mandates

Call Me Maybe: Cardiac variants fail to predict risk in prospective study

TAVR provides fertile market for firm: Vivasure Medical picks up CE mark for percutaneous vascular closure device

MDD's Company Stock Report

Opponents say not a wise move: Indian government urged to rethink health care price caps

Daily M&A: S&N completes acquisition of Blue Belt Holdings for $275M

Patent Watch: Biomarker Strategies gains key patents for core technology

Products

People in Places

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...